Spots Global Cancer Trial Database for palifermin
Every month we try and update this database with for palifermin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma | NCT00434161 | Multiple Myelom... | Palifermin befo... Placebo Palifermin befo... | 18 Years - 70 Years | Swedish Orphan Biovitrum | |
| Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation | NCT00189488 | Graft Versus Ho... Hematologic Mal... | Palifermin Placebo Conditioning Re... Allogeneic stem... Methotrexate | 18 Years - | Swedish Orphan Biovitrum | |
| A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Stage 2B or 3 Locally Advanced, Colon Cancer | NCT00393822 | Colon Cancer | palifermin placebo | 18 Years - | Amgen | |
| Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant | NCT04177004 | Allogeneic Hema... Hematopoietic a... | Allogeneic Hema... Cyclophosphamid... Etoposide Fractionated St... Goat Milk Palifermin Sirolimus Tacrolimus | 12 Years - | City of Hope Medical Center | |
| Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma | NCT00482846 | Mucositis Multiple Myelom... | Palifermin melphalan questionnaire a... autologous peri... quality-of-life... | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies | NCT01421173 | Lymphoma | Vorinostat Gemcitabine Busulfan Melphalan Stem Cell Infus... Rituximab G-CSF Palifermin Dexamethasone a... | 12 Years - 65 Years | M.D. Anderson Cancer Center | |
| A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Stage 2B or 3 Locally Advanced, Colon Cancer | NCT00393822 | Colon Cancer | palifermin placebo | 18 Years - | Amgen | |
| A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer | NCT00131638 | Head and Neck C... | Placebo Palifermin | 18 Years - | Amgen | |
| Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC) | NCT00094861 | Dysphagia Non-Small Cell ... Lung Cancer | Palifermin Placebo Radiotherapy Paclitaxel Carboplatin | 18 Years - | Swedish Orphan Biovitrum | |
| Palifermin After Haploidentical PBSCT | NCT00570999 | Non-Hodgkin's L... Acute Leukaemia Myelodysplastic... Chronic Myeloid... Osteomyelofibro... | Palifermin Placebo | 18 Years - 65 Years | European Society for Blood and Marrow Transplantation | |
| CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma | NCT01746173 | T-cell Non-Hodg... | Cyclophosphamid... Doxorubicin Vincristine Etoposide Prednisone Filgrastim Plerixafor Stem Cell Colle... Palifermin Gemcitabine Busulfan Melphalan Stem Cell Trans... | 18 Years - 70 Years | Dana-Farber Cancer Institute | |
| Palifermin in Preventing Oral Mucositis Caused by Chemotherapy and/or Radiation Therapy in Young Patients Undergoing Stem Cell Transplant | NCT00728585 | Gastrointestina... Malignant Neopl... | Palifermin Placebo | 1 Year - 16 Years | Children's Oncology Group | |
| A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer | NCT00131638 | Head and Neck C... | Placebo Palifermin | 18 Years - | Amgen | |
| Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma | NCT02114502 | Myeloma | Carfilzomib SAHA Gemcitabine Busulfan Melphalan Stem Cell Trans... Palifermin Dexamethasone Caphosol Glutamine Pyridoxine | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Human Lysozyme Goat Milk in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant | NCT03531281 | Hematopoietic a... Hematopoietic C... | Allogeneic Hema... Cyclophosphamid... Etoposide Goat Milk Laboratory Biom... Palifermin Sirolimus Tacrolimus Total-Body Irra... | 12 Years - 60 Years | City of Hope Medical Center | |
| High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease | NCT01200329 | Lymphoma | Gemcitabine Busulfan Melphalan Stem Cell Trans... Palifermin | 12 Years - 70 Years | M.D. Anderson Cancer Center | |
| A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Stage 2B or 3 Locally Advanced, Colon Cancer | NCT00393822 | Colon Cancer | palifermin placebo | 18 Years - | Amgen | |
| Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma | NCT00482846 | Mucositis Multiple Myelom... | Palifermin melphalan questionnaire a... autologous peri... quality-of-life... | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer | NCT00004061 | Leukemia Lymphoma Oral Complicati... | filgrastim palifermin cyclophosphamid... etoposide ifosfamide peripheral bloo... quality-of-life... radiation thera... | 18 Years - 65 Years | National Cancer Institute (NCI) | |
| Palifermin After Haploidentical PBSCT | NCT00570999 | Non-Hodgkin's L... Acute Leukaemia Myelodysplastic... Chronic Myeloid... Osteomyelofibro... | Palifermin Placebo | 18 Years - 65 Years | European Society for Blood and Marrow Transplantation | |
| Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer | NCT00004061 | Leukemia Lymphoma Oral Complicati... | filgrastim palifermin cyclophosphamid... etoposide ifosfamide peripheral bloo... quality-of-life... radiation thera... | 18 Years - 65 Years | National Cancer Institute (NCI) | |
| Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma | NCT00482846 | Mucositis Multiple Myelom... | Palifermin melphalan questionnaire a... autologous peri... quality-of-life... | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Human Lysozyme Goat Milk in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant | NCT03531281 | Hematopoietic a... Hematopoietic C... | Allogeneic Hema... Cyclophosphamid... Etoposide Goat Milk Laboratory Biom... Palifermin Sirolimus Tacrolimus Total-Body Irra... | 12 Years - 60 Years | City of Hope Medical Center | |
| CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma | NCT01746173 | T-cell Non-Hodg... | Cyclophosphamid... Doxorubicin Vincristine Etoposide Prednisone Filgrastim Plerixafor Stem Cell Colle... Palifermin Gemcitabine Busulfan Melphalan Stem Cell Trans... | 18 Years - 70 Years | Dana-Farber Cancer Institute | |
| A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy | NCT00540332 | Head and Neck C... | Placebo palifermin | 18 Years - | Swedish Orphan Biovitrum | |
| Palifermin in Lessening Oral Mucositis in Patients Undergoing Radiation Therapy and Chemotherapy for Locally Advanced Head and Neck Cancer | NCT00360971 | Head and Neck C... Mucositis Pain Radiation Toxic... | palifermin cisplatin placebo neck dissection radiation thera... | 18 Years - | Radiation Therapy Oncology Group | |
| 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome | NCT05139004 | Acute Lymphobla... Acute Myeloid L... Myelodysplastic... Secondary Acute... | Allogeneic Hema... Basiliximab Fludarabine Pho... Indium In 111-D... Melphalan Palifermin Total Lymphoid ... Total Marrow Ir... Yttrium Y 90 Ba... | 60 Years - | City of Hope Medical Center | |
| Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant | NCT04177004 | Allogeneic Hema... Hematopoietic a... | Allogeneic Hema... Cyclophosphamid... Etoposide Fractionated St... Goat Milk Palifermin Sirolimus Tacrolimus | 12 Years - | City of Hope Medical Center | |
| A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer | NCT00131638 | Head and Neck C... | Placebo Palifermin | 18 Years - | Amgen | |
| 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome | NCT05139004 | Acute Lymphobla... Acute Myeloid L... Myelodysplastic... Secondary Acute... | Allogeneic Hema... Basiliximab Fludarabine Pho... Indium In 111-D... Melphalan Palifermin Total Lymphoid ... Total Marrow Ir... Yttrium Y 90 Ba... | 60 Years - | City of Hope Medical Center | |
| Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies | NCT00410982 | Leukemia Lymphoma Myeloma | Busulfan Gemcitabine Melphalan Hematopoietic C... Rituximab for P... Palifermin | 18 Years - 69 Years | M.D. Anderson Cancer Center | |
| Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer | NCT00101582 | Mucositis Solid Tumors Stomatitis Head and Neck C... Squamous Cell C... | Placebo palifermin cisplatin chemo... Radiotherapy | 18 Years - | Swedish Orphan Biovitrum | |
| Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer | NCT00004132 | Drug/Agent Toxi... Leukemia Lymphoma Multiple Myelom... Oral Complicati... Radiation Toxic... | filgrastim palifermin cyclophosphamid... etoposide ifosfamide quality-of-life... radiation thera... | 12 Years - 65 Years | National Cancer Institute (NCI) | |
| A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Subjects With Acute Leukemias Undergoing HSCT | NCT00460421 | Leukemia | Palifermin Total Body irra... Chemotherapy | 1 Year - 16 Years | Swedish Orphan Biovitrum | |
| Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation | NCT02356159 | Myelodysplastic... Hodgkin's Lymph... Non-Hodgkin's L... Acute Leukemia Multiple Myelom... | Rituximab Conditioning ch... TMS FLAG EPOCH-F Hematopoietic s... Palifermin | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Palifermin in Lessening Oral Mucositis in Patients Undergoing Radiation Therapy and Chemotherapy for Locally Advanced Head and Neck Cancer | NCT00360971 | Head and Neck C... Mucositis Pain Radiation Toxic... | palifermin cisplatin placebo neck dissection radiation thera... | 18 Years - | Radiation Therapy Oncology Group | |
| Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma | NCT03100877 | Plasma Cell Leu... Plasma Cell Mye... | Autologous Hema... Cyclophosphamid... Filgrastim Laboratory Biom... Lenalidomide pheresis Melphalan Palifermin Total Marrow Ir... | 18 Years - 70 Years | City of Hope Medical Center | |
| Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation | NCT01746849 | Leukemia Multiple Myelom... Myelodysplastic... Non-Hodgkin's L... | Palifermin Lupron peripheral bloo... Total-Body Irra... Thiotepa Cyclophosphamid... Degarelix | 18 Years - 60 Years | Memorial Sloan Kettering Cancer Center | |
| High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease | NCT01200329 | Lymphoma | Gemcitabine Busulfan Melphalan Stem Cell Trans... Palifermin | 12 Years - 70 Years | M.D. Anderson Cancer Center | |
| Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | NCT01085617 | Leukemia Mucositis Oral Complicati... | palifermin rituximab cyclophosphamid... cytarabine daunorubicin hy... etoposide fludarabine pho... imatinib mesyla... melphalan mercaptopurine methotrexate nelarabine pegaspargase vincristine sul... allogeneic hema... total-body irra... | 25 Years - 65 Years | University College, London | |
| Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant | NCT04177004 | Allogeneic Hema... Hematopoietic a... | Allogeneic Hema... Cyclophosphamid... Etoposide Fractionated St... Goat Milk Palifermin Sirolimus Tacrolimus | 12 Years - | City of Hope Medical Center | |
| Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant | NCT04177004 | Allogeneic Hema... Hematopoietic a... | Allogeneic Hema... Cyclophosphamid... Etoposide Fractionated St... Goat Milk Palifermin Sirolimus Tacrolimus | 12 Years - | City of Hope Medical Center | |
| Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE) | NCT00109031 | Cancer Lymphoma Leukemia | palifermin Total Body Irra... Cyclophosphamid... Etoposide Placebo | 18 Years - | Swedish Orphan Biovitrum | |
| High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma | NCT01237951 | Myeloma | Palifermin Dexamethasone Gemcitabine Busulfan Melphalan Stem Cell Trans... G-CSF | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome | NCT05139004 | Acute Lymphobla... Acute Myeloid L... Myelodysplastic... Secondary Acute... | Allogeneic Hema... Basiliximab Fludarabine Pho... Indium In 111-D... Melphalan Palifermin Total Lymphoid ... Total Marrow Ir... Yttrium Y 90 Ba... | 60 Years - | City of Hope Medical Center | |
| A Study of Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy and Concurrent Chemotherapy | NCT00626639 | Mucositis Head and Neck C... | Placebo palifermin Radiotherapy Cisplatin | 18 Years - | Swedish Orphan Biovitrum | |
| 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome | NCT05139004 | Acute Lymphobla... Acute Myeloid L... Myelodysplastic... Secondary Acute... | Allogeneic Hema... Basiliximab Fludarabine Pho... Indium In 111-D... Melphalan Palifermin Total Lymphoid ... Total Marrow Ir... Yttrium Y 90 Ba... | 60 Years - | City of Hope Medical Center | |
| Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype | NCT02589145 | Lymphoma | Lenalidomide Vorinostat Gemcitabine Busulfan Melphalan Rituximab Dexamethasone Caphosol Glutamine Pyridoxine Enoxaparin Stem Cell Trans... Palifermin | 15 Years - 65 Years | M.D. Anderson Cancer Center | |
| A Study of Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy and Concurrent Chemotherapy | NCT00626639 | Mucositis Head and Neck C... | Placebo palifermin Radiotherapy Cisplatin | 18 Years - | Swedish Orphan Biovitrum | |
| A Study of Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy and Concurrent Chemotherapy | NCT00626639 | Mucositis Head and Neck C... | Placebo palifermin Radiotherapy Cisplatin | 18 Years - | Swedish Orphan Biovitrum | |
| Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation | NCT01746849 | Leukemia Multiple Myelom... Myelodysplastic... Non-Hodgkin's L... | Palifermin Lupron peripheral bloo... Total-Body Irra... Thiotepa Cyclophosphamid... Degarelix | 18 Years - 60 Years | Memorial Sloan Kettering Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
